Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14week, randomized, double-blind, placebo-controlled trial

Diabetic Medicine, 01/03/2011

To evaluate the efficacy, safety and pharmacokinetics of pregabalin in treating neuropathic pain associated with diabetic peripheral neuropathy in Japanese patients. A randomized, double–blind, placebo–controlled, multicentre 14 week clinical trial was conducted. Pregabalin was well tolerated; somnolence (26%), dizziness (24%), peripheral oedema (13%) and weight gain (11%) were the most common adverse events and generally were reported as mild to moderate.

Print Article Summary